Proton beam therapy for hepatocellular carcinoma with bile duct invasion.


Journal

BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547

Informations de publication

Date de publication:
03 Aug 2023
Historique:
received: 07 04 2023
accepted: 20 07 2023
medline: 7 8 2023
pubmed: 4 8 2023
entrez: 3 8 2023
Statut: epublish

Résumé

Hepatocellular carcinoma (HCC) with bile duct invasion (BDI) (BDIHCC) has a poor prognosis. Moreover, due to the paucity of reports, there is no consensus regarding optimal management of this clinical condition yet. The aim of this study was to clarify the efficacy and safety of proton beam therapy (PBT) for BDIHCC. Between 2009 and 2018, 15 patients with BDIHCC underwent PBT at our institution. The overall survival (OS), local control (LC), and progression-free survival (PFS) curves were constructed using the Kaplan-Meier method. Toxicities were assessed using the Common Terminology Criteria of Adverse Events version 4.0. The median follow-up time was 23.4 months (range, 7.9-54.3). The median age was 71 years (range, 58-90 years). Many patients were Child A (n = 8, 53.3%) and most had solitary tumors (n = 11, 73.3%). Additionally, most patients had central type BDI (n = 11, 73%). The median tumor size was 4.0 cm (range, 1.5-8.0 cm). The 1-, 2-, and 3-year OS rates were 80.0%, 58.7% and 40.2%, respectively, and the corresponding LC and PFS rates were 93.3%, 93.3%, and 74.7% and 72.7%, 9.7%, and 0.0%, respectively. Acute grade 1/2 dermatitis (n = 7, 46.7%), and grades 2 (n = 1, 6.7%) and 3 (n = 1, 6.7%) cholangitis were observed. Late toxicities such as grade 3 gastric hemorrhage and pleural effusion were observed. No toxicities of grade 4 or higher were observed. PBT was feasible with tolerable toxicities for the treatment of BDIHCC.

Identifiants

pubmed: 37537527
doi: 10.1186/s12876-023-02897-y
pii: 10.1186/s12876-023-02897-y
pmc: PMC10401805
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

267

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Eur Radiol. 2018 Apr;28(4):1540-1550
pubmed: 29124380
J Hepatol. 2003 Feb;38(2):200-7
pubmed: 12547409
Cardiovasc Intervent Radiol. 2010 Dec;33(6):1168-79
pubmed: 20058008
Semin Intervent Radiol. 2006 Jun;23(2):119-25
pubmed: 21326755
Trans Am Clin Climatol Assoc. 1964;75:111-6
pubmed: 21408638
Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):831-6
pubmed: 19304408
PLoS One. 2017 May 4;12(5):e0176827
pubmed: 28472122
Strahlenther Onkol. 2009 Dec;185(12):782-8
pubmed: 20013087
J Clin Oncol. 2005 Mar 20;23(9):1839-46
pubmed: 15774777
J Gastrointest Surg. 2009 Mar;13(3):492-7
pubmed: 19011945
Gastroenterol Res Pract. 2014;2014:604971
pubmed: 24723944
J Radiat Res. 2012 Nov 1;53(6):945-53
pubmed: 22966173
Gan To Kagaku Ryoho. 2014 Nov;41(12):2113-5
pubmed: 25731440
PLoS One. 2017 Jan 18;12(1):e0170153
pubmed: 28099460
J Vasc Interv Radiol. 2003 Dec;14(12):1535-42
pubmed: 14654488
J Radiat Res. 2021 Jul 10;62(4):682-687
pubmed: 34036362
Am J Gastroenterol. 1993 Sep;88(9):1410-5
pubmed: 8395764
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1039-45
pubmed: 20888707
Korean J Hepatobiliary Pancreat Surg. 2015 Nov;19(4):167-72
pubmed: 26693236
Radiother Oncol. 2017 May;123(2):240-245
pubmed: 28366501
Anticancer Res. 2014 Aug;34(8):4367-72
pubmed: 25075073
Ann Surg. 2007 Jun;245(6):909-22
pubmed: 17522517
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):460-6
pubmed: 19427743
Diagn Interv Imaging. 2015 Nov;96(11):1169-75
pubmed: 26292615
Mol Clin Oncol. 2020 Jan;12(1):31-35
pubmed: 31814974
Front Oncol. 2021 Nov 05;11:723455
pubmed: 34804918
Oncol Lett. 2018 Sep;16(3):3593-3602
pubmed: 30127966
J Cancer Res Clin Oncol. 2020 Mar;146(3):711-720
pubmed: 31776663
Cancer Sci. 2017 Mar;108(3):497-503
pubmed: 28012214
World J Gastroenterol. 2003 Mar;9(3):385-91
pubmed: 12632482
Phys Med Biol. 1996 Aug;41(8):1331-9
pubmed: 8858723
World J Gastroenterol. 2004 May 15;10(10):1397-401
pubmed: 15133842
Dig Dis Sci. 2017 Apr;62(4):1086-1094
pubmed: 28205111
Br J Radiol. 2020 Jan;93(1105):20190375
pubmed: 31670572
Medicine (Baltimore). 2015 Jan;94(1):e364
pubmed: 25569656

Auteurs

Takashi Iizumi (T)

Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan. iizumi@pmrc.tsukuba.ac.jp.

Toshiyuki Okumura (T)

Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.

Naoyuki Hasegawa (N)

Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Kazunori Ishige (K)

Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Department of Gastroenterology, Kasumigaura Medical Center, Ibaraki, Japan.

Kuniaki Fukuda (K)

Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Department of Gastroenterology, Kasumigaura Medical Center, Ibaraki, Japan.

Emiko Seo (E)

Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Hirokazu Makishima (H)

Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.

Hikaru Niitsu (H)

Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.

Mizuki Takahashi (M)

Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.

Yuta Sekino (Y)

Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.

Hiroaki Takahashi (H)

Department of Radiology, Mayo Clinic, Rochester, USA.

Daichi Takizawa (D)

Department of Radiation Oncology, Hitachi General Hospital, Tsukuba, Japan.

Yoshiko Oshiro (Y)

Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.
Department of Radiation Oncology, Tsukuba Medical Center Hospital, Tsukuba, Japan.

Keiichiro Baba (K)

Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.

Motohiro Murakami (M)

Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.

Takashi Saito (T)

Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.

Haruko Numajiri (H)

Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.

Masashi Mizumoto (M)

Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.

Kei Nakai (K)

Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.

Hideyuki Sakurai (H)

Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH